How should I manage new gastrointestinal or skin irritation that started after beginning citalopram?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Citalopram-Induced Irritation

If you develop new gastrointestinal or skin irritation after starting citalopram, discontinue the medication immediately and contact your prescriber to switch to an alternative antidepressant from a different class, as cross-reactivity between SSRIs can occur despite different chemical structures. 1

Gastrointestinal Irritation Management

Initial Assessment and Symptom Control

  • Nausea is the most common adverse effect of citalopram, occurring in approximately 20% of patients, and is typically mild, transient, and resolves within the first few weeks of treatment. 2, 3

  • If nausea develops, assess whether it is mild-to-moderate and self-limiting (expected to resolve in 1-2 weeks) or severe and persistent (lasting beyond 2-3 weeks). 3, 4

  • For mild-to-moderate nausea during the first 2 weeks, consider symptomatic management with ondansetron 4-8 mg as needed, though evidence for its efficacy in SSRI-induced nausea is limited. 5

  • Take citalopram with food to minimize gastrointestinal irritation, as this simple intervention often reduces nausea severity without compromising drug absorption. 3

When to Discontinue for GI Symptoms

  • Discontinue citalopram immediately if severe nausea with vomiting prevents adequate oral intake, if abdominal pain is severe, or if symptoms persist beyond 3 weeks without improvement. 3, 4

  • Switch to an antidepressant with lower gastrointestinal side effects, such as bupropion SR (starting at 150 mg daily) or mirtazapine (starting at 7.5-15 mg at bedtime), both of which have distinct mechanisms and lower nausea rates. 5, 6

  • Do not switch to another SSRI (such as sertraline, fluoxetine, or paroxetine) if citalopram caused significant GI intolerance, as cross-reactivity and similar side effect profiles exist across the SSRI class. 5, 1

Skin Irritation Management

Recognition of Cutaneous Reactions

  • Citalopram can cause cutaneous adverse reactions including papular erythema, pruritus, purpura, and rarely severe reactions such as leucocytoclastic vasculitis, Stevens-Johnson syndrome, or toxic epidermal necrolysis. 7, 1

  • Skin reactions typically appear within the first week of treatment (median 6 days) but can occur after several weeks of therapy. 1

  • Increased sweating occurs in 15-18% of patients and represents a common, benign side effect that does not require discontinuation unless bothersome. 2, 3

Immediate Action for Skin Reactions

  • Discontinue citalopram immediately at the first appearance of any rash, blisters, peeling skin, mucosal erosions, purpura, or signs of hypersensitivity, as these may herald serious dermatologic reactions. 5, 1

  • Do not rechallenge with citalopram after a cutaneous reaction, as the long elimination half-life (33-36 hours) means symptoms may persist for several weeks even after discontinuation. 2, 1

  • Avoid switching to other SSRIs (fluoxetine, paroxetine, sertraline, fluvoxamine) after a citalopram-induced skin reaction, as cross-reactivity can occur despite different chemical structures. 1

Alternative Antidepressant Selection

  • Switch to an antidepressant from a different class: consider bupropion SR (150 mg daily, titrated to 300-400 mg), mirtazapine (7.5-15 mg at bedtime, titrated to 30-45 mg), or a tricyclic antidepressant such as nortriptyline (10 mg at bedtime, titrated to 30-50 mg). 5, 6

  • For patients with anxiety as the primary indication, consider switching to an SNRI such as venlafaxine extended-release (37.5-75 mg daily, titrated to 150-225 mg) or duloxetine (30 mg daily, titrated to 60 mg), which have different receptor profiles and lower risk of cross-reactivity. 5, 6

Critical Monitoring Requirements

  • Monitor closely for worsening depression, suicidal ideation, behavioral activation, or agitation during the first 1-2 months after discontinuing citalopram or switching medications, as suicide risk is greatest during treatment transitions. 5, 6

  • Assess for discontinuation syndrome when stopping citalopram, characterized by dizziness, anxiety, irritability, sensory disturbances, and flu-like symptoms, though citalopram has a lower risk compared to paroxetine or sertraline. 5, 6, 8

  • Taper citalopram gradually over 1-2 weeks (e.g., reduce from 20 mg to 10 mg for 7 days, then discontinue) to minimize discontinuation symptoms, even when switching due to adverse effects. 5, 6

Common Pitfalls to Avoid

  • Do not continue citalopram hoping that severe GI or skin symptoms will resolve, as serious reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with SSRIs and require immediate discontinuation. 5, 1

  • Do not assume that switching to another SSRI will avoid similar reactions, as cross-reactivity occurs despite different chemical structures. 1

  • Do not abruptly discontinue citalopram without a taper plan, as this increases the risk of discontinuation syndrome even in the setting of adverse effects. 5, 6

  • Do not delay switching to an alternative antidepressant class, as prolonged interruption of antidepressant therapy worsens depression outcomes and increases suicide risk. 6

References

Research

The safety and tolerability of citalopram.

International clinical psychopharmacology, 1996

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Tratamiento del Trastorno de Ansiedad Generalizada Resistente a Monoterapia con Escitalopram

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Escitalopram-Induced Skin Rash: Dermatitis Medicamentosa.

Indian journal of dermatology, 2022

Guideline

Withdrawal Symptoms of Selective Serotonin Reuptake Inhibitors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.